U.S. markets close in 3 hours 45 minutes
  • S&P 500

    3,856.85
    +27.51 (+0.72%)
     
  • Dow 30

    31,283.42
    -118.59 (-0.38%)
     
  • Nasdaq

    13,354.95
    +235.52 (+1.80%)
     
  • Russell 2000

    2,211.49
    +11.32 (+0.51%)
     
  • Crude Oil

    62.33
    -1.20 (-1.89%)
     
  • Gold

    1,718.90
    -56.50 (-3.18%)
     
  • Silver

    26.27
    -1.41 (-5.11%)
     
  • EUR/USD

    1.2090
    -0.0096 (-0.79%)
     
  • 10-Yr Bond

    1.5000
    -0.0180 (-1.19%)
     
  • GBP/USD

    1.3947
    -0.0066 (-0.47%)
     
  • USD/JPY

    106.6450
    +0.4150 (+0.39%)
     
  • BTC-USD

    48,175.48
    -2,718.18 (-5.34%)
     
  • CMC Crypto 200

    968.62
    +35.49 (+3.80%)
     
  • FTSE 100

    6,483.43
    -168.53 (-2.53%)
     
  • Nikkei 225

    28,966.01
    -1,202.26 (-3.99%)
     

Here's Why We're Not Too Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Situation

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.

There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Kiniksa Pharmaceuticals (NASDAQ:KNSA) has seen its share price rise 123% over the last year, delighting many shareholders. Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed.

Given its strong share price performance, we think it's worthwhile for Kiniksa Pharmaceuticals shareholders to consider whether its cash burn is concerning. For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow). The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'.

Check out our latest analysis for Kiniksa Pharmaceuticals

When Might Kiniksa Pharmaceuticals Run Out Of Money?

A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. When Kiniksa Pharmaceuticals last reported its balance sheet in September 2020, it had zero debt and cash worth US$364m. Looking at the last year, the company burnt through US$122m. So it had a cash runway of about 3.0 years from September 2020. Arguably, that's a prudent and sensible length of runway to have. You can see how its cash balance has changed over time in the image below.

debt-equity-history-analysis
debt-equity-history-analysis

How Is Kiniksa Pharmaceuticals' Cash Burn Changing Over Time?

Kiniksa Pharmaceuticals didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. So while we can't look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time. Even though it doesn't get us excited, the 27% reduction in cash burn year on year does suggest the company can continue operating for quite some time. Clearly, however, the crucial factor is whether the company will grow its business going forward. So you might want to take a peek at how much the company is expected to grow in the next few years.

Can Kiniksa Pharmaceuticals Raise More Cash Easily?

While Kiniksa Pharmaceuticals is showing a solid reduction in its cash burn, it's still worth considering how easily it could raise more cash, even just to fuel faster growth. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. Many companies end up issuing new shares to fund future growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations.

Since it has a market capitalisation of US$1.0b, Kiniksa Pharmaceuticals' US$122m in cash burn equates to about 12% of its market value. As a result, we'd venture that the company could raise more cash for growth without much trouble, albeit at the cost of some dilution.

So, Should We Worry About Kiniksa Pharmaceuticals' Cash Burn?

It may already be apparent to you that we're relatively comfortable with the way Kiniksa Pharmaceuticals is burning through its cash. For example, we think its cash runway suggests that the company is on a good path. Its cash burn reduction wasn't quite as good, but was still rather encouraging! After taking into account the various metrics mentioned in this report, we're pretty comfortable with how the company is spending its cash, as it seems on track to meet its needs over the medium term. Readers need to have a sound understanding of business risks before investing in a stock, and we've spotted 3 warning signs for Kiniksa Pharmaceuticals that potential shareholders should take into account before putting money into a stock.

Of course Kiniksa Pharmaceuticals may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.